Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
And before you say I'm a tils and bou shareholder and soon to be accustem shareholder too
That's why it's moving to accustem to prove its true potential.... Tils has other drugs now to prove
It's "worth" that but tils is 190 mil mcap.
So I would believe if the market truly needed their offering, it aced all tests against its peers and then someone was to make an offer thats how it would get there...
But from a fresh listing, we'd have to assume surely no more than 100mil? Maybe as low as 30mil?
Depends what other value is in tils? If this is the plan of course?
If not, whatever comes we'd still have to look at it in a similar way.
Interview with CEO. StemprintER is worth more 2.8b dollars.
https://youtu.be/ggFJ-XX6C5M
Maybe even 1000/1. Or depending on what happens share structure may alter completely...
We aren't listed so that could happen.
So long as we can work out where we was and how we got to where we are going that's fine.
If it is the tils spin out, I wonder how it would be valued? Can't see 100-150 mil. Tils whole mcap is not much more at 190 mil.
If there's also been a placing, placees would want immediate value in either a discount to current SP or to valuation. Leads me to assume it would be a discount to valuation.
That leaves 3 elements to reconcile. Us, placees and existing/qualifying tils share holders.
I'm not fully convinced of the tils spin out yet... but if it is, has it been assigned a value? I'm being lazy and not scouring through their rns. See if anyone knows off the top of their head?
We can then begin to make some assumptions.
If it's as I think and a discount on value (ie listing at a lower price) then we would move north on re-list.
So what do people think the consolidation will be, I have a feeling it will at least 100/1.
Was this the number of share in issue 12,408,442,268, if so then about £124m after consolidation.